DMAA Drugs Made In America Acquisition Corp. - Ordinary Shares
$10.58
Price · May 19, 2026
Fundamentals as of Apr 15, 2026
52W Range
$10–$11
96% of range
Analyst Rating
—
Price Target
—
P/E (TTM)
—
ROE
-82.4%
Net Profit Margin
—
DMAA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$10.58
Market Cap
$111M
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
-82.4%
Debt/Equity
—
52W Range
$10 – $11
DMAA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
DMAA
Peer Median
P/B
-15.3
0.9
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
DMAA
Peer Median
ROA
4.9%
3.1%
ROE
-82.4%
3.9%
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
DMAA
Peer Median
Current Ratio
0.0
1.8
Quick Ratio
0.0
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
DMAA
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
DMAA
Peer Median
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 6
| Metric | Trend | 2025 |
|---|---|---|
| SG&A Expense | $3M | |
| Operating Income | $-3M | |
| Interest Income | $9M | |
| Other Non-op | $9M | |
| Net Income | $6M | |
| EBITDA | $-3M |
Balance Sheet 12
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $6.1K | |
| Prepaid Expense | $6.1K | |
| Current Assets | $12.2K | |
| Total Assets | $240M | |
| Accounts Payable | $222.2K | |
| Current Liabilities | $376.2K | |
| Total Liabilities | $7M | |
| Common Stock | $1.1K | |
| Retained Earnings | $-7M | |
| Stockholders' Equity | $-7M | |
| Liabilities + Equity | $240M | |
| Shares Outstanding | 10,717,143 |
Cash Flow 3
| Metric | Trend | 2025 |
|---|---|---|
| Operating Cash Flow | $-539.2K | |
| Investing Cash Flow | $-231M | |
| Financing Cash Flow | $232M |
Profitability 2
| Metric | Trend | 2025 |
|---|---|---|
| ROA | 4.9% | |
| ROE | -82.4% |
Liquidity & Solvency 2
| Metric | Trend | 2025 |
|---|---|---|
| Current Ratio | 0.0 | |
| Quick Ratio | 0.0 |
Valuation (TTM) 4
| Metric | Trend | 2025 |
|---|---|---|
| Net Income TTM | $6M | |
| Market Cap | $111M | |
| P/B | -15.3 | |
| P / Cash Flow | -206.2 |
Income Statement 6
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| SG&A Expense | $2M | $263.7K | $131.9K | $330.9K | |
| Operating Income | $-2M | $-263.7K | $-131.9K | $-330.9K | |
| Interest Income | $2M | $2M | $2M | $2M | |
| Other Non-op | $2M | $2M | $2M | · | |
| Net Income | $213.0K | $2M | $2M | $1M | |
| EBITDA | · | $-263.7K | $-131.9K | $-330.9K |
Balance Sheet 13
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $6.1K | $717 | $822 | $923 | |
| Prepaid Expense | $6.1K | $27.5K | $48.9K | $70.1K | |
| Current Assets | $12.2K | $28.2K | $49.7K | $71.0K | |
| Total Assets | $240M | $238M | $235M | $233M | |
| Accounts Payable | $222.2K | · | · | · | |
| Accrued Liabilities | · | $302.6K | $147.5K | $132.5K | |
| Current Liabilities | $376.2K | $456.6K | $301.4K | $347.4K | |
| Total Liabilities | $7M | $7M | $7M | $7M | |
| Common Stock | $1.1K | $1.1K | $1.1K | $1.1K | |
| Retained Earnings | $-7M | $-7M | $-6M | $-6M | |
| Stockholders' Equity | $-7M | $-7M | $-7M | $-7M | |
| Liabilities + Equity | $240M | $238M | $235M | $233M | |
| Shares Outstanding | 10,717,143 | 10,517,143 | 10,517,143 | 10,517,143 |
Cash Flow 3
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-125.2K | $-56.1K | $-106.7K | $-251.2K | |
| Investing Cash Flow | $0 | $0 | $0 | $-231M | |
| Financing Cash Flow | $130.6K | $56.0K | $106.6K | $231M |
Profitability 2
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| ROA | · | 1.8% | 1.9% | 1.1% | |
| ROE | · | -59.6% | -64.0% | -35.0% |
Liquidity & Solvency 2
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Current Ratio | · | 0.1 | 0.2 | 0.2 | |
| Quick Ratio | · | 0.0 | 0.0 | 0.0 |
Valuation (TTM) 4
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Net Income TTM | · | $6M | · | · | |
| Market Cap | · | $108M | $107M | $105M | |
| P/B | · | -14.7 | -15.0 | -14.7 | |
| P / Cash Flow | · | · | · | -419.4 |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Net Income | $6M | — |
Balance Sheet
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Current Ratio | 0.0 | — |
| Quick Ratio | 0.0 | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.